Sponsored by:

headline-text-20005

Erik Ridley Headshot
Erik L. Ridley
Nov 24, 2000
Ge12 17 99 small
body-text-20005
Latest in Nuclear Medicine
Post-Pluvicto SPECT/CT with axial fused images of sacrum and sagittal maximum intensity projection of one of the patients who complained of increasing pain in the sacral region (arrows) post therapy.
What side effects do patients report after Pluvicto therapy?
June 5, 2026
SNMMI ShowCast Roundup
June 5, 2026
Advancing molecular imaging together
Sponsored
Advancing molecular imaging together
May 24, 2026
Acquisitions
Alpha Tau, Tolmar strike $196M deal to commercialize Alpha DaRT
June 3, 2026
Related Stories
Dementiasmall
Nuclear Medicine
FDG-PET clears up metabolic murkiness between dementia and Alzheimer's
Positracesmall
CT
SMV wins FDA clearance for Positrace hybrid PET/CT camera
Gammasmall07 19 00 rn
Nuclear Medicine
Gamma Medica sees better lymph node imaging with handheld probe
Advancing molecular imaging together
Sponsor Content
Advancing molecular imaging together
More in Nuclear Medicine
What side effects do patients report after Pluvicto therapy?
By Will Morton
Fatigue, pain flare, nausea, and urinary symptoms are among the most commonly reported immediate side effects of Pluvicto therapy.
June 5, 2026
Post-Pluvicto SPECT/CT with axial fused images of sacrum and sagittal maximum intensity projection of one of the patients who complained of increasing pain in the sacral region (arrows) post therapy.
SNMMI ShowCast Roundup
By Will Morton
Science was the star in Los Angeles at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting.
June 5, 2026
Radiopharmaceutical manufacturers report uneven FDA inspections
By Liz Carey
RMTA lays out radiopharmaceutical regulatory and payment policy issues.
June 4, 2026
Lab Equipment Drug Manufacturing
Alpha Tau, Tolmar strike $196M deal to commercialize Alpha DaRT
By AuntMinnie.com staff writers
Tolmar will make a $20 million equity investment in Alpha Tau at closing and contribute $15 million toward construction of a new U.S. production facility.
June 3, 2026
Acquisitions
SNMMI awards Martin Pomper 2026 Benedict Cassen Prize
By AuntMinnie.com staff writers
The SNMMI has awarded Martin Pomper, MD, PhD, the Benedict Cassen Prize for his contributions toward nuclear medicine research.
June 1, 2026
Martin Pomper, MD, PhD
ASCO: Lu-177 edotreotide yields sustained quality-of-life gains
By Erik L. Ridley
A poster presentation at ASCO 2026 highlighted quantifiable benefits for patients receiving the radiopharmaceutical treatment for GEP-NETs.
May 31, 2026
Asco Thumb
Archeus doses first patient in phase I RPT trial
By AuntMinnie.com staff writers
In preclinical work, Y-90 ARC-706 demonstrated tumor-selective uptake across multiple ICI-treated cancers.
May 27, 2026
Cancertarget
Mevion to install first proton therapy system in Vietnam
By AuntMinnie.com staff writers
Mevion Medical Systems has signed an agreement to install what the firm says will be the first proton therapy system in Vietnam.
May 26, 2026
Business Handshake 400 (1)
Radnostix reports 27% revenue decline in Q1
By AuntMinnie.com staff writers
Radnostix reported a 27% decrease in the first quarter of 2026 compared to the previous year's first quarter.
May 21, 2026
Research Money 400
Niowave breaks ground on $75M Mich. Ac-225 production facility
By AuntMinnie.com staff writers
Niowave has broken ground on its Ac-225 production facility in Lansing, MI, with construction expected to be finished by 2028.
May 21, 2026
Construction Pharmaceutical Manufacturing 400
NRC to ease burden on radiopharmaceutical licensees
By AuntMinnie.com staff writers
The rule would eliminates decommissioning financial assurance (DFA) for all radionuclides with half-lives of 120 days or less.
May 19, 2026
Isotopes1
Plus Therapeutics inks AI deal with Ephemeral Technologies
By AuntMinnie.com staff writers
Plus Therapeutics is a clinical-stage pharmaceutical company developing radiopharmaceutical therapies for CNS cancers.
May 19, 2026
Ai Handshake
Page 1 of 443
Next Page